|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in EGFR, KRAS, erb-b2 receptor tyrosine kinase 2 gene (ERBB2), and BRAF; gene fusions involving anaplastic lymphoma receptor tyrosine kinase gene (ALK), ROS1, and ret proto-oncogene (RET); and Met Proto-Oncogene Tyrosine Kinase (MET) exon 14 skipping were the major drivers in LUAD in Asians, exhibiting mutually exclusive and differing prevalence from those reported in studies of LUAD in non-Asians.
|
27615396 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in human epidermal growth factor receptor 2 (HER2; also known as ERBB2) are found in approximately 2% of lung adenocarcinomas.
|
31469421 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
ANCCA expression was evaluated by immunohistochemistry in 143 surgically resected lung adenocarcinomas and was correlated with clinicopathologic and molecular variables including adenocarcinoma histologic subtypes, tumor, node, metastasis status, relapse-free survival, overall survival, EGFR mutations, KRAS mutations, HER2 mutations and ALK fusions.
|
23775406 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Among the 204 lung ADCs tested, 11 cases (5.4%) carried HER2 exon 20 insertions and 4 cases (2.0%) had BRAF V600E mutation.
|
26102513 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma component.
|
30825613 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We investigated clinical and potential molecular factors associated with HER2-mutant lung adenocarcinoma.
|
22071781 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
|
22908275 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this surgical series, 52 resected lung adenocarcinomas from never-smokers (< 100 cigarettes in a lifetime) at a single institution (Fudan University, Shanghai, China) were analyzed concurrently for mutations in EGFR, KRAS, NRAS, HRAS, HER2, BRAF, ALK, PIK3CA, TP53 and LKB1.
|
20855837 |
2010 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We showed patients with ERBB2-mutated lung adenocarcinoma can respond to targeted therapies, and we identified potential resistance mechanisms upon progression to targeted therapies.
|
28167203 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The FGFR4 mutation is analogous to a reported tumor-specific somatic mutation in ERBB2 and is located in the same exon as a previously reported kinase domain mutation in FGFR4 (Pro712Thr) in a lung adenocarcinoma cell line.
|
17487277 |
2007 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study, the largest to date dedicated to HER2-mutated NSCLC, reinforces the importance of screening for HER2 mutations in lung adenocarcinomas and suggests the potential efficacy of HER2-targeted drugs in this population.
|
23610105 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lung adenocarcinomas with HER2 gene mutation exhibit an aggressive behavior manifesting by higher incidence of local invasion, compared to KRAS and EGFR mutant controls, and a nodal metastatic spread compared to KRAS-mutant control.
|
29906786 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
HER2 mutations were detected in 3% of patients with lung adenocarcinoma in the LCMC.
|
28743157 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this series, 230 resected lung adenocarcinomas from smoker (>100 cigarettes in lifetime) at single center (Shanghai Cancer Center, Shanghai, China) were tested for mutation in EGFR, KRAS, BRAF, HER2, EML4-ALK and PIK3CA.
|
23098378 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the efficacy of first line chemotherapy in patients with advanced HER2-mutant lung adenocarcinomas.
|
29587667 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
HER2 and HER3 expression and activating EGFR mutations in surgically resected lung adenocarcinoma exhibiting ground glass nodules on chest computed tomography and re-classified to stage 0 and IA1 were examined by immunohistochemistry and peptide nucleic acid-locked nucleic acid PCR clamp method, respectively.
|
29473311 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Pulse afatinib at a weekly dosing scheme induced antitumor activity in ERBB2 exon 20 insertion-mutated lung adenocarcinomas.
|
26964772 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The present study evaluated the mutation rate of HER-2 within the wild-type epidermal growth factor receptor (EGFR) lung adenocarcinoma population in China.
|
27793199 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Human epidermal growth factor receptor 2 (HER2, ERBB2) mutations occur in 3% of lung adenocarcinomas.
|
27565914 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
|
15753357 |
2005 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study showed that in addition to lung adenocarcinomas, ERBB2 kinase domain mutation occurs in other common human cancers such as gastric, breast, and colorectal cancers, and suggested that alterations of ERBB2-mediated signaling pathway by ERBB2 mutations alone or together with K-RAS mutations may contribute to the development of human cancers.
|
16397024 |
2006 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
104 consecutively resected lung adenocarcinomas from 396 non-smoker females (less than 100 cigarettes in a lifetime) at a single institution (Tongji University, Shanghai, China) were analyzed for mutations in EGFR, EML4-ALK, KRAS, HER2, BRAF, and PIK3CA.
|
22707299 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Results We treated 18 patients with advanced HER2-mutant lung adenocarcinomas.
|
29989854 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic HER2 mutations are present in 2-4% of lung adenocarcinomas, but the relevant clinical trials are unsatisfactory.
|
30527195 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this study, we reported the first clinical evidence of efficacy generated by afatinib, the irreversible HER family inhibitor, targeting HER2 S310Y single site mutation in lung adenocarcinoma.
|
29561699 |
2018 |